Alicia Chang, NP
Family · San Francisco, CANPI 1376245100
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,990 of the $7,599 with a category attached, or 65.7%. 26 manufacturers reported payments, led by Medtronic at 32.2% of the total. Reporting peaked in 2023 at $4,116 and has fallen 71.6% since, to $1,169 in 2025. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $57.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Relievant Medsystems, Inc.$1K
- Saluda Medical Americas, Inc.$801
- AbbVie$719
- Lundbeck LLC$424
- Si-bone, Inc.$248
- plus $1K from 20 others
Across 10 payments — averaging $3780.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Global Blood Therapeutics, Inc.$38K
What the payments were for
- Speaking & faculty fees$340%
- Travel & lodging$2,52133%
- Food & beverage$4,99066%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 36 | $2,449 |
| Relievant Medsystems, Inc. | 8 | $1,461 |
| Saluda Medical Americas, Inc. | 9 | $801 |
| AbbVie | 23 | $719 |
| Lundbeck LLC | 6 | $424 |
| Si-bone, Inc. | 7 | $248 |
| Vertos Medical, Inc. | 6 | $200 |
| Collegium Pharmaceutical, Inc. | 8 | $178 |
| MML US, Inc. | 1 | $141 |
| Curonix LLC | 2 | $139 |
| Revance Therapeutics, Inc. | 1 | $130 |
| Galderma Laboratories, L.p. | 2 | $120 |
| Merz North America, Inc. | 3 | $96 |
| Bioventus LLC | 2 | $87 |
| Averitas Pharma Inc. | 3 | $66 |
| Axsome Therapeutics, Inc. | 1 | $50 |
| Pfizer | 3 | $45 |
| Johnson & Johnson | 1 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Lilly USA, LLC | 2 | $38 |
| BD | 1 | $34 |
| Stryker | 1 | $22 |
| ERMI LLC | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$5,117
- INTELLIS ADAPTIVESTIM$1,521
- Evoke$342
- VYEPTI$261
- ReActiv8$141
- DAXXIFY$130
- QULIPTA$124
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$123
- BOTOX$116
- VANTA ADAPTIVESTIM$103
How this compares
$7,599 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 17 | $15,205 |
| Buprenorphine | 22 | $8,603 |
| Pregabalin | 65 | $2,903 |
| Gabapentin | 215 | $1,848 |
| Celecoxib | 81 | $1,407 |
| Lidocaine | 16 | $1,042 |
| Diclofenac Sodium | 103 | $851 |
| Cyclobenzaprine Hcl | 35 | $465 |
| Tizanidine Hcl | 69 | $403 |
| Methylprednisolone | 54 | $301 |
| Tramadol Hcl | 48 | $252 |
| Meloxicam | 32 | $188 |
| Ibuprofen | 11 | $177 |
| Cephalexin | 63 | $154 |
| Alprazolam | 14 | $21 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $178 | $15,20517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in San Francisco
- Gabriel SchwartzSan Francisco$166K
- Annika EhrlichSan Francisco$128K
- Monica VolzSan Francisco$96K
- Bethany KinseySan Francisco$33K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.